More on ALNY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $272.67 |
|
|||
| Open | $272.40 | ||||
| 52 Wk High | $109.10 | ||||
| 52 Wk Low | $31.38 | ||||
| Day High | $278.30 | ||||
| Day Low | $270.01 | ||||
| P/E | N/A | ||||
| EPS | $-1.45 | ||||
| Volume | 982,808 | ||||
- Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
- Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data
- Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
- Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure
- Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities
- Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley
- Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY
- Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'
Entities mentioned with ALNY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
